Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19.

Nicolas HoertelMarina Sánchez-RicoRaphaël VernetAnne-Sophie JannotAntoine NeurazCarlos BlancoCédric LemogneGuillaume AiragnesNicolas ParisChristel DanielAlexandre GramfortGuillaume LemaitreMélodie BernauxAli BellamineNathanaël BeekerFrédéric Limosinnull null

Published in: Clinical drug investigation (2021)

Our results suggest that chlorpromazine prescribed at a mean daily dose of 70.8 mg (SD 65.3) was not associated with reduced mortality.

Keyphrases

cardiovascular events
physical activity
risk factors
type diabetes